Hepatitis A virus (HAV) infection can stimulate the production of antibodies to structural and nonstructural proteins of the virus. However, vaccination with an inactivated vaccine produces antibodies exclusively to the structural proteins. Current diagnostic assays, such as the Abbott HAVAB test, used to determine exposure to HAV detect antibodies only to the structural proteins and as a result are not able to distinguish between a natural infection and vaccination with an inactivated virus. Therefore, an ELISA was developed that is specific for antibodies to the nonstructural protein 3C of HAV and thus serves to document the occurrence of viral replication. Antibodies to the proteinase were not detected by this assay in serum from HAVAB-seropositive primates that were immunized with inactivated HAV. However, antibodies to the proteinase were detected in the serum of all primates experimentally infected with virulent HAV and in the serum of naturally infected humans.
Hepatitis A virus (HAV) is a picornavirus that causes acute
is the only nonstructural protein of HAV to date that has been expressed from a recombinant vector to yield a functional proliver disease in humans as well as in nonhuman primates. As with other viruses of the picornavirus family, the genome of HAV can tein [4 -8] . The recombinant 3C proteinase was chosen for the ELISA because it can be recovered from Escherichia coli as be divided into three regions that encode the proteins of the virus. The structural proteins, which form the viral capsid, are encoded a soluble protein that can be purified by standard biochemical methods. by the P1 region, and the nonstructural proteins, which include a viral proteinase, a polymerase, and other proteins involved in
In this study, we determined whether the ELISA could detect anti-3C in sera from chimpanzees and tamarins that had been replication, are encoded by the P2 and P3 regions.
During a natural infection, the immune system of the infected experimentally infected with virulent or attenuated HAV and compared the results with those from animals that had been individual can produce antibodies to both the structural and nonstructural proteins [1, 2] , whereas an inactivated vaccine immunized with an inactivated vaccine or immune serum globulin (ISG). We also determined if the ELISA could detect antiinduces antibodies only to the structural proteins [3] . Therefore, the commercial diagnostic procedures that identify antibodies 3C in humans who were naturally infected with HAV. solely to structural proteins cannot distinguish between an individual who has experienced a natural infection and one who Materials and Methods has been vaccinated with the current vaccine, which consists of inactivated whole virus. For diagnostic, safety, and epidemiExpression and purification of 3C. The plasmid pET-3CD*, ologic reasons it is important to distinguish between antibodies which contains the entire 3C gene and 70 N-terminal amino acids that are elicited by vaccination and those resulting from infecof 3D from the HAS-15 strain of HAV, has been described previously [9] . Plasmid pET-3CD* was transformed into competent tion. Therefore, we have developed an ELISA that can serve BL21 cells. After the transformation, individual colonies were seas a marker of HAV replication, since it is specific for antibodlected, and bacteria were cultured in N-Z amine medium containing ies to the 3C proteinase, a nonstructural protein of HAV.
50 mg/mL ampicillin. Once the optical density at 595 nm reached The 3C proteinase, which is encoded by the P3 region, is 0.5, isopropyl thiogalactopyranoside was added to a final concenan enzyme responsible for processing the HAV polyprotein. It tration of 0.5 mM. Thirty minutes later, the antibiotic rifampicin was added to reduce bacterial protein expression. Three hours after induction, bacteria were harvested by centrifugation and resus-analyzed for 3C proteinase content by Western blot using rabbit vaccine (SmithKline Beecham) containing strain HM-175 (1332 and 1380) or by intravenous inoculation of Ç10,0000 TCID 50 of antibodies to the protein. The fractions containing 3C were pooled and concentrated in a Centricon 10 microconcentrator. The proteinlive attenuated HM-175 (1309 and 1333) and then challenged with 1000 CID 50 of live wild type . Chimpanzees 88A02 ase was purified further on a column of Sepharose 300SW (Pharmacia). The protein was eluted off the column in TRIS-buffered and 88A04 were inoculated intravenously with a 10% liver suspension containing live AGM-27 (not titered), a simian strain of HAV; saline, pH 7.5. A final purification step involved binding the proteinase on a column of hydroxyapatite (BioRad, Hercules, CA) they were later sequentially challenged intravenously with 1000 CID 50 of wild type HM-175 and Ç100,000 CID 50 of wild type and eluting it with a linear gradient of 10-400 mM KH 2 PO 4 . The activity of the 3C proteinase was determined by cleavage of in SD-11 [12] . Tamarin 682 was inoculated intrahepatically with infectious transcribed RNA encoding a virulent HAV strain, while vitro-generated radiolabeled polyprotein substrate as described by Schultheiss et al. [8] . The protein concentration was determined tamarin 683 was inoculated intravenously with 100,000 CID 50 of an attenuated strain of HM-175. Human serum samples were colby a commercially available assay (BioRad).
ELISA development. The 3C proteinase was diluted in 50 mM lected from persons exposed to HAV during an outbreak of hepatitis A at a military institution [13] and from laboratory staff memcarbonate buffer (pH 9.6) to a final concentration of 1 mg/mL. One hundred microliters of the diluted 3C proteinase was placed bers who had been naturally exposed to HAV, vaccinated with HAV vaccine, or never exposed to HAV. in each well of 96-well microtiter plates and incubated overnight at 4ЊC. After incubation, the wells were washed four times with Serum samples from inoculated chimpanzees and tamarins were analyzed for alanine aminotransferase (ALT) and isocitrate dehy-PBS-1% Tween 20 and then incubated with 100 mL/well blocking buffer (PBS with 10% fetal calf serum and 1% gelatin) for 1 h at drogenase (ICD) with commercial assays (Metpath, Rockville, MD). Levels of ALT or ICD equal to or greater than twice the 37ЊC. After removal of the blocking buffer, the wells were washed four times with PBS-1% Tween 20. One hundred microliters of mean prechallenge value were indicative of biochemical evidence of hepatitis. Primates were housed under BL-2 biohazard containserum from chimpanzees, tamarins, or humans was diluted in blocking buffer, added to the microtiter plate, and then incubated ment. for 1 h at 37ЊC. After this incubation, the microtiter plate was washed four times with PBS-1% Tween 20. Anti-human IgG or IgM labeled with horseradish peroxidase (HRP) (Organon Teknika
Results
Cappel, West Chester, PA) was used to detect antibodies to the HAV proteinase in chimpanzees and humans, while anti-New Anti-3C proteinase in chimpanzees. A chimpanzee (1442) after seroconversion to structural proteins and peak enzyme even though replication of the vaccine virus was insufficient to stimulate anti-3C antibodies. The vaccine dose was not sufproduction. Chimpanzee 1451, which produced significantly higher levels of anti-proteinase than did chimpanzee 1373, seficient to result in seroconversion to the structural proteins in the absence of replication. roconverted to 3C proteinase on week 6 after inoculation, 1 week after seroconversion to structural proteins.
Passive immunization with ISG prevents disease but does not necessarily prevent viral replication [2] . The 3 chimpanzees Vaccination with a nonreplicating virus should induce antibodies to the structural proteins but not to nonstructural pro-(1374, 1396, and 1420) (table 1, figure 1E ) that were inoculated with ISG and then challenged intravenously with wild type teins. Serum from chimpanzees that were immunized with either an attenuated or an inactivated vaccine were tested for an HM-175 seroconverted to the structural proteins but did not exhibit an increase in serum ALT levels and, therefore, did not antibody response to 3C proteinase. Two chimpanzees vaccinated with an inactivated HM-175 vaccine (1332 and 1380) develop hepatitis. However, all 3 animals produced antibodies to the proteinase, indicating that viral replication had occurred. seroconverted to the structural proteins after vaccination and did not exhibit elevated serum liver enzyme levels after immuAll 3 chimpanzees developed anti-3C titers §1:100. Immunization with inactivated HAV vaccine did boost antibodies to the nization or after challenge with virulent HM-175 (table 2) . Antibodies to the nonstructural proteinase 3C were not detected structural proteins (data not shown) but did not increase the anti-3C antibody titer in chimpanzee 1374 ( figure 1E ). in chimpanzee 1332 ( figure 1C, table 2 ) either before or after challenge with HM-175, indicating that the vaccination with Infection of chimpanzees 88A02 ( figure 1F ) and 88A04 (table 2) with the simian strain of HAV, AGM-27, was associated with the inactivated vaccine in this case protected against significant replication of the virus. However, chimpanzee 1380, which also a low level of viral replication [12] and caused seroconversion to HAV structural proteins in the absence of hepatitis. Although the remained anti-3C -negative after vaccination with inactivated vaccine ( figure 1D ), did exhibit anti-3C reactivity after intrave-AGM-27 virus did replicate, albeit to a low level in both animals [12] , only chimpanzee 88A04 transiently displayed detectable levnous challenge with a high dose of HM-175. Therefore, in this animal, vaccination provided protection against hepatitis but els of anti-3C (titer of 1:20) 3 months after inoculation with AGM-27 (data not shown). Following the AGM-27 infection, the not against infection, since replication of the challenge virus occurred. Chimpanzees 1309 and 1333, vaccinated with an chimpanzees were challenged intravenously first with HM-175 and later with SD-11. Neither chimpanzee developed hepatitis A, attenuated vaccine, produced antibodies to the structural proteins and mounted a fully protective immune response, since as indicated by stable ALT levels. However, there did appear to be a boost in antibodies to 3C after the SD-11 challenge in chimthey did not develop hepatitis or become infected after challenge (table 2) . Neither animal produced antibody to 3C after panzee 88A02 ( figure 1F ) and after both the HM-175 challenge and SD-11 challenge in chimpanzee 88A04 (data not shown), vaccination. This suggests that the attenuated virus was able to stimulate production of antibodies to the structural protein, indicating low-level replication of the viruses.
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Anti-3C proteinase in tamarins.
To determine if the ELISA 6 after inoculation. Antibody to 3C peaked during week 7 and was still detectable at week 17 after inoculation. could monitor antibody production to 3C in primates other than chimpanzees, we analyzed serum from HAV-infected tamarins.
Another tamarin, 683 (figure 3B), was inoculated intravenously with an attenuated virus. This animal seroconverted to Tamarin 682 had been infected by intrahepatic transfection with RNA transcribed from an HAV cDNA clone (8Y), which the structural proteins, but serum ICD levels were much lower than those in tamarin 682, which had been infected with viruencodes a virus with a wild type phenotype [14] . This tamarin exhibited a peak serum ICD level and seroconverted to the lent virus. Even though there were indications of viral replication, such as fecal viral shedding, antibodies to the 3C protein-HAV structural proteins at week 5 after inoculation ( figure  3A ). Antibodies to 3C proteinase were first detected at week ase did not reach significant levels in this animal. Anti-3C proteinase in humans. Serum samples from patients 9 young adults who were seropositive for antibodies to the structural proteins of HAV because of natural exposure to the who developed hepatitis A were analyzed to determine if antibodies to the proteinase could be detected in humans. The pavirus did test positive for antibody to 3C (data not shown). Eight of the 9 with anti-structural antibodies (including 2 of tients had been exposed to HAV during an outbreak of hepatitis A on a military base [13] . Three patients (B, C, and D) seroconthe 3 with anti-3C antibodies) were from countries where HAV was endemic and had not experienced any clinical signs of verted to the structural proteins of HAV and exhibited increased serum ALT levels (data not shown). Antibody to the 3C proteindisease. Therefore, the exact time of exposure is unknown. However, since subclinical infections are most common in ase was detected in the serum of all 3 of these patients (figure 4). However, patient A did not seroconvert to the structural young children, exposure most likely occurred many years previously. The third subject became infected with HAV via expoproteins of HAV and was subsequently determined to have chronic non-A, non-B hepatitis. This patient also remained negasure in the laboratory. The sample that was tested for antibody to 3C was collected 7 years after that person had initially tive for antibody to the 3C proteinase (figure 4).
In a separate study, sera from 17 persons who had tested seroconverted to the structural proteins of HAV. negative for antibodies to the structural proteins of HAV also tested negative for antibody to the 3C proteinase (data not Discussion shown). In addition, sera from 4 human subjects who had been immunized with an inactivated HAV vaccine produced anti-
The data from this study demonstrated that HAV-infected humans, chimpanzees, and tamarins produced antibodies to the bodies to the HAV structural proteins but tested negative for antibody to the 3C proteinase (data not shown). The sera from HAV 3C proteinase. Previous studies, based on an immunoprecipitation assay, demonstrated the production of antibodies that the vaccinees were collected at various times ranging from 11 months to 4 years after the initial inoculation. In contrast, 3 of reacted with polyproteins encoded by the entire P2 and P3 regions, but specificity to individual nonstructural proteins was The anti-proteinase antibodies usually were produced concurrently with or immediately after the elevation in serum liver not determined. [3, 15] . Although the immunoprecipitation procedure detects antibodies to the nonstructural proteins, it is not enzyme levels. This result correlated with previous observations of antibodies to the P2 and P3 proteins as a whole [3] . practical because of the time and materials needed to perform the procedure and because of its level of sensitivity. Therefore
In addition, our results suggested that, in general, animals that had more severe infections, as measured by higher levels of we developed an ELISA as an alternative method for monitoring antibodies that signal viral replication. We chose the 3C serum liver enzymes, produced higher titers of anti-proteinase antibodies. Further investigation will be needed to determine proteinase as substrate for the ELISA because it is the only nonstructural protein of HAV to date that has been produced if there is a direct correlation between these two parameters. The ELISA was able to confirm low levels of viral replicain large quantities in a recombinant system and because it can be purified as an enzymatically active and presumably native tion after challenge of 3 passively immunized chimpanzees (1374, 1396, 1420) that did not exhibit signs of clinical disease. enzyme [6, 8] . The data from the present study indicated that antibodies that reacted with 3C proteinase in an ELISA format In addition, chimpanzee 1380, which developed antibodies to the structural proteins after vaccination with an inactivated were produced by humans, chimpanzees, and tamarins following infection with HAV.
HM-175 vaccine, produced low levels (1:20) of antibodies to 3C after challenge with wild type HM-175. The presence of The ELISA detected anti-3C at titers of 1:10 -1:1000 in serum. The results suggested that, in general, antibodies to the anti-proteinase indicated that viral replication occurred in the presence of antibodies to the structural proteins. Since there proteinase did not persist as long as did antibodies to the structural proteins. However, antibodies to 3C were detectable in was no increase in serum ALT levels, and polymerase chain reaction analyses of fecal samples were negative for virus exsome chimpanzees for as long as 2 years.
The versatility of the assay was demonstrated by the fact cretion, the antibodies to 3C proteinase were the only indicators that replication of the virus had occurred. The replication of that it recognized antibodies elicited by 3 different HAV strains. Serum from chimpanzees that were infected with strains HAV in chimpanzee 1380 may be in part due to the fact that the challenge was one thousand times the dose needed for HM-175, SD-11, or AGM-27 contained anti-proteinase antibodies that reacted with the 3C protein of a fourth strain, HASinfection. In addition, the challenge was given intravenously, which allows for a more direct infection of the liver, thereby 15, the source of the antigen in the ELISA. One explanation for the wide versatility is that the 3C gene is one of the most limiting viral interaction with circulating antibody. Inoculation with an attenuated HAV vaccine apparently can conserved regions of the HAV genome. The proteinase from HAV strain HAS-15 differs from the proteinase of wild type result in limited viral replication and seroconversion to the structural proteins in the absence of an antibody response to HAV strain HM-175 by only one amino acid and from the proteinase of strain AGM-27 by nine amino acids. In addition, the 3C proteinase. This was documented in chimpanzees 1309 and 1333, which were both vaccinated with an attenuated strain the assay detected anti-3C in sera from two lower primate species as well as in sera from humans.
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